Search for a trial

A phase III prospective, two-cohort non-randomized, multi-centre, multinational, open label study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as therapy in patients with operable Her2-positive early breast cancer.

The main purpose of this study is to determine the side effects of trastuzumab when it is given by each of these subcutaneous injection methods. The study will also gather information about whether and when the cancer comes back after taking…

Management of low-risk ductal carcinoma in situ (low-risk DCIS): a non-randomized, multicenter, non-inferiority trial; standard therapy versus active surveillance.

The primary end-point is ipsilateral invasive breast tumor-free rate at 10 years. Secondary end-points are among others: overall survival, breast cancer-specific survival, mastectomy rate and patient reported outcomes.To determine whether low- risk…

The effect of Hyperbaric OxygeN therapy on brEast cancer patients with late radiation toxicitY

To assess whether HBOT reduces pain, and improves physical functioning and QoL in breast cancer patients with late radiation toxicity.